An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs CB 03 01 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors Cassiopea
- 06 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 06 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2018.
- 25 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.